XXII - Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session | Benzinga
Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-expected fourth-quarter loss.
Kodiak Sciences posted a quarterly loss of $1.13 per share, compared to market expectations for a loss of 77 cents per share.
Kodiak Sciences shares dipped 19.9% to $5.97 on Thursday.
Here are some other stocks moving in today's mid-day session.
Gainers
- Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares jumped 430% to $25.35 after the company announced it acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio. The company also announced a private placement financing of up to $185 million.
- Xilio Therapeutics, Inc. (NASDAQ: XLO) gained 146% to $1.58 after the company announced an exclusive license agreement with Gilead Sciences for a tumor-activated IL-12 program. The company announced a $11.3 million private placement equity financing.
- Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) shares climbed 80% to $1.5395. Biodexa's MTX110 showed promise in extending life expectancy against aggressive brain cancers.
- Ontrak, Inc. (NASDAQ: OTRK) gained 55% to $0.9239.
- Binah Capital Group, Inc. (NASDAQ: BCG) gained 48% to $14.05 after dipping more than 20% on Wednesday.
- Kidpik Corp. (NASDAQ: PIK) gained 40.7% to $4.5999. Kidpik recently regained compliance with the Nasdaq minimum bid price requirement.
- Allego N.V. (NASDAQ: ALLG) rose 32.8% to $1.7650.
- Akanda Corp. (NASDAQ: AKAN) gained 28% to $0.2053 after the company announced a plan to evaluate opportunities in Bitcoin, Blockchain and AI applications in the cannabis industry.
- Destiny Tech100 Inc. (NASDAQ: DXYZ) rose 26% to $22.15.
- REX American Resources Corporation (NYSE: REX) gained 23.2% to $54.15 following upbeat earnings.
- Nutriband Inc. (NASDAQ: NTRB) gained 23% to $4.98. Nutriband recently provided a clinical and regulatory path overview for its AVERSA Fentanyl patch.
- Summit Therapeutics Inc. (NASDAQ: ...